Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease
Baylor College of Medicine
52 participants
Feb 15, 2022
INTERVENTIONAL
Conditions
Summary
Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD. This trial will investigate the effects of supplementing glycine and N-acetylcysteine vs. alanine as placebo on these defects in AD, and examine the effects on cognition.
Eligibility
Inclusion Criteria4
- Age 55-85 years;
- Gradual and progressive memory loss for more than 1 year, with a Montreal Cognitive Assessment score of 10-20;
- Amyloid positivity on PET scan;
- Availability of a study partner.
Exclusion Criteria8
- hospitalization in past 3 months;
- use of insulin medications;
- untreated thyroid disease;
- creatinine levels \>1.5 mg/dL;
- hemoglobin concentration \<11.0 g/dL;
- known liver disease, or AST/ALT level \>2x ULN;
- untreated depression or other severe psychiatric disorders;
- pregnancy or nursing (unlikely in this population)
Interventions
The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)
The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)
The placebo arm will supplement Alanine
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04740580